Allergic rhinitis, especially when persistent (PER) and associated with asthma heavily impairs patients' quality of life (QoL). This Italian study assessed the effect of mometasone furoate nasal spray (MFNS) on the QoL of patients with PER and asthma.
52 adults patients used momethasone 200 μg/day or placebo for 28 days.
The total 5-symptom score (T5SS) for rhinitis, the asthma symptom score and the sum of the two [global symptoms score (GSS)] were recorded daily. The primary outcome was the change in the Rhinasthma global summary (GS) at the end of treatment.
Momethasone produced a significant change in the Rhinasthma GS and improved symptoms.
The authors concluded that in in patients with PER rhinitis and intermittent asthma, momethasone nose spray improves the QoL and the burden of respiratory symptoms. Treating rhinitis may affect the asthma-related QoL.
Limitations of the study: The study relied only on subjective criteria such as patient symptoms, and no objective criteria such as FEV1 were included in the assessment of respiratory function.
Severe asthma (click to enlarge the image).
Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. Clin Exp Allergy. 2010 Dec 1. doi: 10.1111/j.1365-2222.2010.03660.x. Baiardini I, Villa E, Rogkakou A, Pellegrini S, Bacic M, Compalati E, Braido F, Le Grazie C, Canonica GW, Passalacqua G.
Poor asthma control? – then look up the nose. The importance of co-morbid rhinitis in patients with asthma http://goo.gl/0nNZg
Image source: Illustration for "Aquiline or Roman Nose", Wikipedia, GNU Free Documentation License.